Table of Contents
What changed
Revenue fell 40.5% to $0.4m from $0.7m, against a long-running cost base that delivered a net loss of $664.5m versus $525.1m in HY22, a 26.6% deterioration. With no income tax or discontinued-operation adjustment disclosed, PBT and NPAT move together, so the 26.6% decline is the clean operating read. Operating cash outflow narrowed marginally to $498.5m from $502.1m. The balance sheet tells the larger story: a $1b convertible note was added (no prior-period borrowings were disclosed), total liabilities rose 477.8% to $1.4b, and total equity fell 38.7% to $9.6b. Cash edged up to $966.9m, leaving roughly $33.1m of net debt. No dividend was declared, consistent with HY22.
What matters
- Capital structure reset. The introduction of a $1.0bn convertible note, against only $11.0m of incremental cash, is the most consequential disclosure. It signals either refinancing or deployment intent that the extracts do not explain, and it converts a previously unlevered position into a modestly net-debt balance sheet.
- Equity erosion outpaces the P&L loss. Equity fell $6.1b while the reported loss was $664.5m, implying roughly $5.4bn of equity movement outside net profit — most likely reserve or revaluation-driven. This matters more to book value and ROE (weakening to -5.3% from -3.4%) than the headline loss itself.
- Revenue is immaterial to the result. A 40.5% revenue decline on a $0.4m base is not the driver of the loss; the operating cost base and balance-sheet remeasurement are. Investors should read this as an investment/holding-vehicle result, not an operating-company result.
Expectations
No stated target, forward-work balance, or formal guidance was disclosed. The only shape context is FY22, where HY22 represented 55.6% of full-year revenue and 49.3% of full-year NPAT — a broadly front-loaded pattern. Annualising HY23 revenue implies roughly $0.8m for FY23, about 33.8% below FY22's $1.2m. On NPAT, HY23's $664.5m loss already exceeds HY22's half-share of the $1.1b FY22 loss, so unless the second half reverses, the full-year loss will be larger than FY22's. The release provides no basis to assess whether that trajectory is expected to continue.
Quality of result
Very little of this result is operating in nature. Revenue is de minimis, no EBITDA or segment measure was disclosed, and the loss is not meaningfully explained by trading. Operating cash outflow of $498.5m is broadly in line with the prior period, so the P&L deterioration does not appear to be working-capital-assisted in either direction. The most durable takeaway is structural rather than earnings-driven: $1.0bn of new convertible debt, a 38.7% fall in equity, and a 31.0% contraction in total assets to $11b. Inventories were flat at $314.3m; receivables, payables and capex were not disclosed, so operating working capital cannot be reconstructed.
Unresolved
- What does the $1.0bn convertible note fund, on what terms, and with what conversion mechanics?
- What drove the ~$5.4bn of equity movement not explained by the reported loss — revaluation, impairment, capital return, or reclassification?
- Why does a $0.4m revenue base support a $498.5m operating cash outflow — what are the principal cost lines and are they recurring?
- Is there a discontinued operation or disposal behind the asset-base contraction that the provided extracts do not name?
This briefing cannot assess the nature of the business NTL actually operates, the terms of the convertible note, or the composition of the equity movement, because none of these are disclosed in the supplied extracts.
Key metrics
| Metric | HY23 | HY22 | Change |
|---|---|---|---|
| Revenue | $0.39m | $0.66m | -40.5% ↓ |
| Net profit after tax | −$664.5m | −$525.1m | -26.6% ↓ |
| Net cash inflow from operating activities | −$498.5m | −$502.1m | +0.7% ↑ |
| Final dividend per share | — | 0.0c | — |
| Operating profit | −$664.5m | −$525.1m | -26.6% ↓ |
| Total assets | $11b | $15.9b | -31.0% ↓ |
Analytical metrics
| Metric | HY23 | HY22 | Context |
|---|---|---|---|
| Net debt | $33.1m | — | — |
| Gross borrowings | $1b | — | — |
| Payout ratio vs NPAT | 0.0% | — | — |
| ROE (annualised) | -5.3% | -3.4% | Weakening |
| HY22 share of FY22 revenue | 55.6% | — | Other half was 44.4% |
| HY22 share of FY22 NPAT | 49.3% | — | Other half was 50.7% |
| Profit from continuing operations | −$665m | — | — |
This analysis was generated using Annolyse, an AI-powered tool that analyses NZX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.